SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal

Bulletin Express03-10

Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.

The announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.

The current board composition comprises: • Executive directors: Lian Wanyong and Yang Binghua • Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying • Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru

Investors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135632537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135632537","market":"us","top_or_hot":-1,"title":"SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal","media":"Bulletin Express","content":"<p>Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.</p>\n<p>The announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.</p>\n<p>The current board composition comprises:\n• Executive directors: Lian Wanyong and Yang Binghua  \n• Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying  \n• Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru</p>\n<p>Investors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.</p>\n<p>The announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.</p>\n<p>The current board composition comprises:\n• Executive directors: Lian Wanyong and Yang Binghua  \n• Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying  \n• Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru</p>\n<p>Investors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"","article_id":"1135632537","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135632537","pubTimestamp":1773132215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药控股(01099)定于2026年3月20日召开董事会批准2025财年业绩及股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.\nThe announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.\nThe current board composition comprises:\n• Executive directors: Lian Wanyong and Yang Binghua  \n• Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying  \n• Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru\nInvestors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135632537","isCrawlerRequest":true}